These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9282640)

  • 1. Liposomes as drug delivery system in leishmaniasis.
    Kshirsagar NA; Gokhale PC; Pandya SK
    J Assoc Physicians India; 1995 Jan; 43(1):46-8. PubMed ID: 9282640
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of visceral leishmaniasis with a 10 day course of L-ampB-LRC (Bombay), a liposomal amphotericin B.
    Bodhe PV; Pathare AV; Kshirsagar NA; Pandya SK
    J Assoc Physicians India; 1996 Mar; 44(3):222. PubMed ID: 9251329
    [No Abstract]   [Full Text] [Related]  

  • 3. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Berman JD
    Clin Infect Dis; 1999 Jan; 28(1):49-51. PubMed ID: 10391695
    [No Abstract]   [Full Text] [Related]  

  • 4. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Meyerhoff A
    Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of cutaneous leishmaniasis with liposomal amphotericin B].
    del Rosal Rabes T; Baquero-Artigao F; Gómez Fernández C; García Miguel MJ; de Lucas Laguna R
    An Pediatr (Barc); 2010 Aug; 73(2):101-2. PubMed ID: 20615769
    [No Abstract]   [Full Text] [Related]  

  • 6. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
    Manfredi R; Marinacci G; Calza L; Passarini B
    Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
    [No Abstract]   [Full Text] [Related]  

  • 7. Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.
    Borrelli P; Imperato A; Murdaca G; Scudeletti M
    Ann Ital Med Int; 2000; 15(2):169-71. PubMed ID: 10920508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis.
    Brown M; Noursadeghi M; Boyle J; Davidson RN
    Br J Dermatol; 2005 Jul; 153(1):203-5. PubMed ID: 16029352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
    Minodier P; Robert S; Noël G; Blanc P; Retornaz K; Garnier JM
    Arch Pediatr; 2005 Jul; 12(7):1102-8. PubMed ID: 15964525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABLE: a new and improved amphotericin B for visceral leishmaniasis?
    Berman J
    Am J Trop Med Hyg; 2009 May; 80(5):689-90. PubMed ID: 19407106
    [No Abstract]   [Full Text] [Related]  

  • 12. [Leishmania braziliensis: report of a pediatric imported case with response to liposomal amphotericin B].
    Campos-Muñoz L; Quesada-Cortés A; Martín-Díaz MA; Rubio-Flores C; de Lucas-Laguna R
    Actas Dermosifiliogr; 2007; 98(1):42-4. PubMed ID: 17374332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of visceral leishmaniasis with liposomal amphotericin B.
    Lagler H; Matt U; Sillaber C; Winkler S; Graninger W
    Acta Biomed; 2006; 77 Suppl 2():22-5. PubMed ID: 16918063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients.
    Amato VS; Rabello A; Rotondo-Silva A; Kono A; Maldonado TP; Alves IC; Floeter-Winter LM; Neto VA; Shikanai-Yasuda MA
    Acta Trop; 2004 Oct; 92(2):127-32. PubMed ID: 15350864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal polyene antibiotics.
    Ng AW; Wasan KM; Lopez-Berestein G
    Methods Enzymol; 2005; 391():304-13. PubMed ID: 15721388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal Amphotericin B Treatment and the Leishmaniases.
    Berman J
    Am J Trop Med Hyg; 2019 Oct; 101(4):727-728. PubMed ID: 31482790
    [No Abstract]   [Full Text] [Related]  

  • 17. Liposomal drug delivery system from laboratory to clinic.
    Kshirsagar NA; Pandya SK; Kirodian GB; Sanath S
    J Postgrad Med; 2005; 51 Suppl 1():S5-15. PubMed ID: 16519249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duodenal leishmaniasis after allogeneic hematopoietic SCT.
    Martínez-Losada C; Martin C; Cuenca T; Torres A
    Bone Marrow Transplant; 2013 Apr; 48(4):614-5. PubMed ID: 23042493
    [No Abstract]   [Full Text] [Related]  

  • 19. Mucocutaneous leishmaniasis treated with liposomal amphotericin B.
    Lambertucci JR; Silva LC
    Rev Soc Bras Med Trop; 2008; 41(1):87-8. PubMed ID: 18368279
    [No Abstract]   [Full Text] [Related]  

  • 20. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.
    Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S
    J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.